Effectiveness and safety of different estradiol regimens in transgender women (TREAT study): Protocol for a randomized controlled trial

Samuel Cortez  
*Washington University School of Medicine in St. Louis*

Dominic Moog  
*Washington University School of Medicine in St. Louis*

Christopher Lewis  
*Washington University School of Medicine in St. Louis*

Kelley Williams  
*Washington University School of Medicine in St. Louis*

Cynthia Herrick  
*Washington University School of Medicine in St. Louis*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa_4](https://digitalcommons.wustl.edu/oa_4)

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

**Recommended Citation**

Cortez, Samuel; Moog, Dominic; Lewis, Christopher; Williams, Kelley; Herrick, Cynthia; Fields, Melanie; Gray, Teddi; Guo, Zhaohua; Nicol, Ginger; and Baranski, Thomas, "Effectiveness and safety of different estradiol regimens in transgender women (TREAT study): Protocol for a randomized controlled trial." JMIR Research Protocols. 12, e53092 (2023).  
[https://digitalcommons.wustl.edu/oa_4/3316](https://digitalcommons.wustl.edu/oa_4/3316)
Protocol

Effectiveness and Safety of Different Estradiol Regimens in Transgender Women (TREAT Study): Protocol for a Randomized Controlled Trial

Samuel Cortez1, MD, MSc; Dominic Moog2, BA; Christopher Lewis1, MD; Kelley Williams3, MD; Cynthia Herrick3,4, MD, MPH; Melanie Fields5,6, MD, MSc; Teddi Gray7, CCRC; Zhaohua Guo7, PhD, MS; Ginger Nicol7*, MD; Thomas Baranski3*, MD, PhD

1Division of Pediatric Endocrinology, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States
2Washington University School of Medicine, St Louis, MO, United States
3Division of Endocrinology, Diabetes, and Lipid Metabolism, Department of Medicine, Washington University School of Medicine, St Louis, MO, United States
4Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, United States
5Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States
6Department of Neurology, Washington University School of Medicine, St Louis, MO, United States
7Department of Psychiatry, Washington University School of Medicine, St Louis, MO, United States
*these authors contributed equally

Corresponding Author:
Samuel Cortez, MD, MSc
Division of Pediatric Endocrinology
Department of Pediatrics
Washington University School of Medicine
660 S Euclid Ave
Campus Box 8116
St Louis, MO, 63110
United States
Phone: 1 314 454 6051
Email: scortez@wustl.edu

Abstract

Background: Current guidelines for gender-affirming hormone therapy (GAHT) for transgender women are mostly based on clinical experience from experts in the field and treatments used on postmenopausal women. While care is currently provided with the best available evidence, there is a critical gap in knowledge about the safest and most effective estradiol routes of administration for GAHT in transgender women; this statement is supported by the World Professional Association for Transgender Health on their Standards of Care for the Health of Transgender and Gender Diverse People, version 8. Furthermore, the reported rates of cardiometabolic adverse events in transgender women highlight the importance of investigating changes in lipoproteins, glucose, and insulin sensitivity, among other markers while receiving GAHT.

Objective: This study aims to evaluate the degree of testosterone suppression achieved at 1, 6, and 12 months in treatment-naive transgender women when randomized to GAHT with estradiol and spironolactone as antiandrogens. As a secondary aim, this study will assess the treatment effect on metabolic and coagulation factors from baseline to 6 and 12 months after initiating GAHT.

Methods: This is a prospective pilot, open-label, randomized clinical trial conducted at an adult transgender clinic in a tertiary medical center. The 3 treatment arms include once-daily sublingual 17-β estradiol, twice-daily sublingual 17-β estradiol, and transdermal 17-β estradiol. All participants received spironolactone as an antiandrogen. Transgender women aged 18 to 45 years who are being evaluated for the initiation of GAHT with 17-β estradiol and did not have a history of coagulopathy, cigarette smoking, liver disease, dyslipidemia requiring treatment, or use of gonadotropin-releasing hormone agonist were eligible to enroll. The main outcome is the total testosterone suppression at 1 and 6 months after the initiation of GAHT, and the secondary outcome is to assess treatment effect in a lipid panel; homeostatic model assessment for insulin resistance; coagulation factors II, IX, and
Introduction

Transgender individuals experience gender discordance between their self-identified gender and biological birth sex [1-3]. Some transgender individuals experience gender dysphoria, which the Diagnostic and Statistical Manual of Mental Disorders defines as clinically significant distress or impairment in social, occupational, or other key areas of functioning. Increasing numbers of adolescents seek care at gender identity centers in Western countries [4,5].

Studies using short self-reports of gender identity and its variants suggest that 0.17% to 1.3% of adolescents and young adults identify as transgender [6]. Even using the conservative estimate of 0.3%, the number of people living in the United States who identify as transgender is nearly 1 million [7]. Given the widespread acknowledgment of the health care needs of this population, priority should be given to those actions that will ensure timely access to appropriate care. Such action includes coverage of transition care and a requirement to ensure safe, effective, appropriate, and sensitive care in health centers [8-10].

Transgender women seek gender-affirming hormone therapy (GAHT) to reach physical features consistent with their gender identity [11-13]. The goal of GAHT for transgender women is to achieve feminine features and maintain estradiol levels within the normal woman range while suppressing endogenous testosterone [11]. The current approach to GAHT is not uniform and is used off-label for this indication. It also depends on the cost of the regional health care system and availability of estrogens and antiandrogens.

A typical regimen includes estrogen to provide feminizing effects in conjunction with therapy to block testosterone (antiandrogens or gonadotropin-releasing hormone analogs) [14]. The currently preferred estrogen formulation that can be provided in tablets, patches, and injections is 17-β estradiol, and spironolactone is the most prescribed antiandrogen in the United States.

The Transgender Estradiol Affirming Therapy (TREAT) study offers a rigorous and reproducible approach to answer important questions regarding GAHT in transgender women, specifically, the most effective 17-β estradiol regimen to suppress testosterone levels to 50 ng/dL, as currently recommended.

Methods

Overview

This prospective pilot, open-label, randomized clinical trial compares the testosterone-suppressing effects of 3 commonly used 17-β estradiol regimens in transgender women adults initiating GAHT. The 17-β estradiol regimens used in this trial include once-daily sublingual 17-β estradiol, twice-daily sublingual 17-β estradiol, and transdermal 17-β estradiol patch.

The primary end point is testosterone suppression from baseline to 1 and 6 months with secondary evaluation of treatment-related

Results:

This study was funded in March 2022, and enrollment concluded in August 2022. It was concluded in July 2023, and currently, the results are being analyzed for publication.

Conclusions:

The Transgender Estradiol Affirming Therapy (TREAT) study offers a rigorous and reproducible approach to answer important questions regarding GAHT in transgender women, specifically, the most effective 17-β estradiol regimen to suppress testosterone levels to 50 ng/dL, as currently recommended.

Trial Registration:

ClinicalTrials.gov NCT05010707; https://clinicaltrials.gov/study/NCT05010707

International Registered Report Identifier (IRRID): DERR1-10.2196/53092

KEYWORDS

transgender research; transgender health; clinical trial; estrogen; transwomen

https://www.researchprotocols.org/2023/1/e53092

doi: 10.2196/53092
changes in lipid panel; homeostatic model assessment for insulin resistance; coagulation factors II, IX, and XI; Von Willebrand factor; activated protein C resistance; protein C; and protein S at baseline, 6 months, and 12 months after therapy is initiated.

The study took place at the Washington University Transgender Center. Patients aged 18 to 45 years who were being evaluated for the initiation of GAHT with 17-β estradiol and did not have a history of coagulopathy, cigarette smoking, liver disease, dyslipidemia requiring treatment, or use of gonadotropin-releasing hormone agonist were eligible to enroll. Initially, the study was limited to those aged 18-30 years and with BMI <30 kg/m², but these were later removed to increase the population available to screen and participate in the study.

Power analyses indicated that 12 participants per group would provide 80% power to detect differences in total testosterone between groups when the true difference between groups is 230 ng/dL. The type I error probability is .05.

We will also use a likelihood-based mixed-effects model to separately evaluate the effects of time and treatment on metabolic and coagulation factors from baseline to 6 and 12 months after the initiation of treatment. We will also determine if there is any correlation between estradiol and estrone levels with coagulation factors as suggested by other studies.

**Ethical Considerations**

The Washington University in St. Louis Institutional Review Board approved the study protocol (IRB# 202104092) in May 2021, which was executed in accordance with the Declaration of Helsinki. Participants received financial compensation for their time and costs associated with participation in the study ($30 per visit).

**Study Procedures**

Participants who met eligibility criteria and provided informed consent were randomized 1:1:1 to either once-daily sublingual 17-β estradiol, twice-daily sublingual 17-β estradiol, or a transdermal 17-β estradiol patch. All participants received spironolactone as an antiandrogen. The dosing protocol is shown in Table 1.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Once-daily sublingual</th>
<th>Twice-daily sublingual</th>
<th>Transdermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-β estradiol</td>
<td>Starting dose: 2 mg once a day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase by 2 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone</td>
<td>Starting dose: 50 mg daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase by 50 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maximum dose: 200 mg/day</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initial evaluation included a comprehensive medical history, physical examination, and baseline laboratory testing. During the initial visit, patients were randomized and started on spironolactone and 17-β estradiol based on their treatment group assignment. The initial evaluation was completed in conjunction with the treating endocrinologist with follow-up conducted by the study investigator.

Once participants started their GAHT treatment assignment, they underwent a titration phase in which the hormone profile including estradiol, total testosterone, estrone, and basic metabolic panel was assessed every 4 weeks until total testosterone was less than 50 mg/dL. If the total testosterone is above goal, 17-β estradiol and spironolactone doses were adjusted based on their group dosing regimens as depicted in Table 1.

Anthropometric measurements and metabolic and coagulation factors were obtained at baseline, 24 weeks, and 52 weeks (Table 2). Blood testing was conducted before their morning dose for participants randomized to sublingual 17-β estradiol or the morning when the transdermal 17-β estradiol patch is due for replacement.
Table 2. Study visits and laboratory testing.

<table>
<thead>
<tr>
<th>Laboratory testing</th>
<th>Baseline</th>
<th>Titration phase</th>
<th>6 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric measurements</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hormone profile</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total testosterone</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrone</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic metabolic panel</td>
<td>✓✓✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver function panel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting serum glucose</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting total insulin</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting lipid panel</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coagulation factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor II activity</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor IX activity</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor XI activity</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Von Willebrand Factor Antigen</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activated protein C resistance (APCR)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein C activity</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free protein S antigen</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results

This study was funded in March 2022, and enrollment concluded in August 2022. It was concluded in July 2023, and currently, the results are being analyzed for publication.

Discussion

Expected Findings

The Transgender Estradiol Affirming Therapy (TREAT) study offers a rigorous and reproducible approach to answer important questions regarding the GAHT in transgender women. Specifically, the study will determine if significant differences in testosterone suppression between once-daily, twice-daily, or transdermal 17β-estradiol exist.

This study will also provide insights into metabolic and coagulation changes in transgender women on GAHT with sublingual and transdermal 17β estradiol and spironolactone as antiandrogens. These outcomes, with the GAHT used in this study, have not been explored in prior studies.

In addition, this study will provide insights into the best strategies and most reliable methods to inform the design of future, fully powered randomized clinical trials.

Limitations

Due to a lack of uniformity on the current prescription patterns for GAHT, we decided to conduct this study using the most common regimens prescribed in our clinical setting with no prior studies describing their effects on metabolic and coagulation factors. Hence, it may not be representative of other approaches to GAHT in transgender women, including estradiol valerate or cypionate, which were not included in the study.

Conclusions

The proposed study addresses areas of research that have been determined as important by the most recent World Professional Association for Standards of Care for the Health of Transgender and Gender Diverse People, version 8, including the most effective estrogen regimen (route of administration and dosing schedule), while providing insights on metabolic and coagulation factor changes with concurrent use of spironolactone, which has not been explored previously. Furthermore, this study provides insight into methodology and statistics that will inform larger clinical trials.
Acknowledgments
The Washington University Institute of Clinical and Translational Sciences and the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences grant UL1TR002345 funded this study.

Authors' Contributions
SC, GN, TB, and MF contributed to the conceptualization, methodology, statistical analysis, reviewing, and editing protocol. DM, TG, and ZG contributed to the study administration. CH and KW assisted with patient recruitment and reviewed and edited the paper.

Conflicts of Interest
MF declares equity ownership in Proclara Biosciences and consulting for Global Blood Therapeutics. CH is a consultant for Teladoc Health.

Multimedia Appendix 1
Peer review report from Washington University Institute of Clinical and Translational Sciences. [PDF File (Adobe PDF File), 181 KB - Multimedia Appendix 1]

Multimedia Appendix 2
CONSORT checklist. [DOC File, 219 KB - Multimedia Appendix 2]

References


### Abbreviations

- **GAHT**: gender-affirming hormone therapy
- **TREAT**: Transgender Estradiol Affirming Therapy

©Samuel Cortez, Dominic Moog, Christopher Lewis, Kelley Williams, Cynthia Herrick, Melanie Fields, Teddi Gray, Zhaohua Guo, Ginger Nicol, Thomas Baranski. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 22.12.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.